MoonLake Immunotherapeutics
Closed (deSPAC)Profile in progress
- What it is
- A private company preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Helix Acquisition Corp (HLXA) — closed (despac).
- What you should know
- The deal carries a $150M minimum-cash condition — heavy redemptions can break it.
What the company says about itself
Web research — not audited[WEB-INTEL 2026-08-26] 2 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering" [https://ir.moonlaketx.com/press-releases/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. Apr 5 2022" [https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-ag-announces-closing-business/]
Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
MoonLake Immunotherapeutics is merging with Helix Acquisition Corp (HLXA) currently marked Closed (deSPAC).
| Headline equity value | — |
| Minimum cash to close | $150M |
Structure per SEC accession(s) 0001213900-22-007163. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is MoonLake Immunotherapeutics going public?
MoonLake Immunotherapeutics has an approved merger with the SPAC Helix Acquisition Corp (HLXA). Deal status: Closed (deSPAC).
Does MoonLake Immunotherapeutics have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.